Pfizer wins EU approval for MabThera biosimilar
The drug will be available to treat certain cancers and autoimmune conditions
Read More
Tag: MabThera
Sandoz dumps US filing for biosimilar rituximab
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
Read More
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read More
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read More
Sandoz launches MabThera, Enbrel biosimilars in the UK
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read More
Novartis’ MabThera biosimilar wins EU nod
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Read More
Mundipharma to launch Mabthera biosimilar in EU markets
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
Read More
Sandoz’ MabThera biosimilar to get EU review
European regulators have agreed to review Sandoz’ biosimilar to Roche’s oncology/immunology blockbuster rituximab.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
